NewGen Announces Closing of $1.25 Million Public Offering

The financing combines ordinary shares with pre-funded warrants to purchase up to 17,732,143 additional Class A Ordinary Shares.

Rhea-AI Summary

NewGenIvf Group (NASDAQ: NIVF) closed its public offering on September 30, 2026, raising approximately $1.25 million in gross proceeds.

The offering comprised 125,000 Class A Ordinary Shares at $0.07 each and pre-funded warrants to purchase up to 17,732,143 Class A Ordinary Shares at $0.06999 per warrant. Each warrant has a $0.00001 per-share exercise price. Gross proceeds exclude placement agent fees and other offering expenses. NewGenIvf expects to use net proceeds together with existing cash for investment in K25.ai, restructuring debt securities, working capital including manufacturing and deployment of Nodexus cell-sorting machines, and general corporate purposes. Aegis Capital acted as exclusive placement agent.

4 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointCompleted offering raised approximately $1.25 million in gross proceeds on September 30, 2026. 7.2× market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.NewGenIvf plans to use net proceeds and existing cash for investment in K25.ai.
• Minor point. Forward-looking: it has not happened yet and may not happen.NewGenIvf plans to use net proceeds and existing cash for restructuring debt securities.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned working-capital use includes manufacturing and deployment of Nodexus machines in the cell-sorting business.

Negative

• Major point125,000 Class A Ordinary Shares at $0.07 each add dilution for existing holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrants at $0.06999 each permit up to 17,732,143 additional shares at a $0.00001 per-share exercise price.
• Minor pointPlacement agent fees and other offering expenses reduce proceeds available to NewGenIvf.

News Explained

The offering closed on September 30, 2026: it included 125,000 Class A shares and immediately exercisable pre-funded warrants for up to 17,732,143 more; exercise converts warrants into shares, reducing existing holders’ percentage ownership if exercised.

Key Figures

Gross proceeds: Approximately $1.25 million Aggregate securities: 17,857,143 Class A ordinary shares: 125,000 +5 more

Gross proceeds

Approximately $1.25 million

Public offering; before placement agent fees and other offering expenses

Aggregate securities

17,857,143

Class A ordinary shares or pre-funded warrants in lieu thereof

Class A ordinary shares

125,000

Securities included in the offering

Pre-funded warrants

17,732,143

Warrants to purchase Class A ordinary shares

Ordinary share offering price

$0.07 per share

Public offering price

Pre-funded warrant price

$0.06999 per warrant

Public offering price

Warrant exercise price

$0.00001 per share

Pre-funded warrants

Transaction close

September 30, 2026

Offering closed

Previous Offering Reports

1 past event · Latest: Sep 28

Same Type 1 event

1. Sep 28

   Public offering

   24h Move

   -79.1%

   Pricing announcement set offering terms later confirmed when the transaction closed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, form f-1

2 terms

pre-funded warrants financial

"Pre-Funded Warrants to purchase up to 17,732,143 Class A Ordinary Shares."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

form f-1 regulatory

"A registration statement on Form F-1 (No. 333-298442)"

A Form F-1 is the document a non-U.S. company files with U.S. regulators when it wants to sell stock or other securities to U.S. investors. It lays out the company’s business, finances, risks and how the offering will work, acting like a product manual and ingredient list so investors can judge what they’re buying. For investors, it’s a key source of verified information used to compare opportunities and assess potential reward and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BANGKOK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $1.25 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consisted of an aggregate of 17,857,143 Class A Ordinary Shares or pre-funded warrants to purchase Class A Ordinary Shares in lieu thereof (the “Pre-Funded Warrants”), comprising 125,000 Class A Ordinary Shares and Pre-Funded Warrants to purchase up to 17,732,143 Class A Ordinary Shares. The public offering price was $0.07 per Class A Ordinary Share and $0.06999 per Pre-Funded Warrant, which equals the public offering price per Class A Ordinary Share less the $0.00001 per share exercise price of the Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full.

Aggregate gross proceeds to the Company were approximately $1.25 million. The transaction closed on September 30, 2026. The Company expects to use the net proceeds from the offering, together with its existing cash, for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in the cell-sorting business, and general corporate purposes.

Aegis Capital Corp. acted as the exclusive placement agent for the offering. Han Kun Law Offices LLP acted as U.S. counsel to the Company. Kaufman & Canoles, P.C. acted as U.S. counsel to Aegis Capital Corp.

A registration statement on Form F-1 (No. 333-298442) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 20, 2026 was declared effective by the SEC on September 28, 2026. The offering was made only by means of a prospectus. A final prospectus describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus, which provides more information about the Company and such offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NewGen

NewGenIVF Group is a technology-forward, diversified growth company, pursuing opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in the UAE’s Ras Al Khaimah Emirate; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did NewGenIvf raise in its public offering, and when did it close?

NewGenIvf raised approximately $1.25 million in gross proceeds, and the offering closed on September 30, 2026. That amount is before placement agent fees and other offering expenses payable by the company.

When can NIVF public offering pre-funded warrants be exercised?

The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The exercise price is $0.00001 per Class A Ordinary Share.